Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population
Comparing the Australian and New Zealand experiences in the evolving COVID-19 landscape highlights differences in policy and prescribing practice.
Call for tenders (HaDEA): Framework contracts to speed up the development of and access to next-generation therapeutics for infectious diseases
The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, acute respiratory distress syndrome (ARDS) or sepsis resulting from infections.
European Medicines Agency (EMA) 2025 Annual Report
The report summarises EMA's work in evaluating and monitoring human and veterinary medicines, including approval numbers for 2025.
COMBINE programme launches phase 2 of the pilot coordinated assessment procedure for combined studies
To apply to the September round, sponsors must submit their expressions of interest by 23 August 2026.
Event: 10th European Congress of Virology 2027
Organised by the European Society for Virology
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection.
Quantifying and combating zoonotic viruses poised for emergence: Using multiplex receptor screening and decoy engineering technologies
A new and unique paradigm shift toward proactive antiviral interventions centered on host-identified multivalent “decoy” receptor therapeutics that can impose high evolutionary barriers to resistance, even in convergent evolution scenarios.
Oseltamivir aziridines are potent influenza neuraminidase inhibitors and imaging agents
The inhibitors demonstrate formidable activity against diverse viral neuraminidases, including H5N1, and further enable imaging and quantification of active NA.
